Researchers reported a case of drug resistance against 2 recently approved antitubercular medications: delamanid and bedaquiline.
For prevention of TB in people with HIV, a single month regimen of rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone.
Number of tuberculosis cases and incidence decreased globally, but more progress is needed to meet targets.
The new interferon-gamma release assay QuantiFERON-TB Gold Plus had good sensitivity in children with pulmonary tuberculosis.
The first-ever UN High-Level Meeting on tuberculosis, in September 2018, resolved that ending the disease is a global priority.
Replacing ethambutol with moxifloxacin has not shown efficacy in tuberculosis treatment success in an 8-week trial.
A short regimen for rifapin-resistant tuberculosis was noninferior to 20-month regimen.
Chronic pulmonary aspergillosis complicates treated pulmonary tuberculosis frequently.